Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

2022-09-20

  • Study

    Randomized, open-label, international, multicenter phase III study
    Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib
    Ripretinib 150 mg (n = 226) or sunitinib 50 mg (4/2, n = 227)

  • Efficacy

    mPFS: 8.3 m vs 7 months (HR, 0.88; P = .36) for KIT exon 11 ITT
    ORR: 23.9% v 14.6%, P = .03

  • Safety

    Grade ≥3 AEs: 26.5% vs 55.2%
    Drug related death: 0 vs 0.5%
    Any grade TRAE: alopecia (64.1%), fatigue (37.7%), myalgia (36.3%) for ripretinib and Palmar-plantar erythrodysesthesia syndrome (51.1%), diarrhea (48.0%), hypertension (47.1%) for sunitinib


    • J Clin Oncol. 2022 Aug 10;JCO2200294.

    Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

    http://doi.org/10.1200/jco.22.00294

    Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022